Please assess the completion status of the following clinical trial:

Trial Title: Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Carcinoid syndrome:~Participants must have histopathologically confirmed neuroendocrine tumor with 4 or more bowel movements per day on standard anti-diarrheal regimen (which includes somatostatin analogs and/or Telotristat Ethyl). Additionally, a plasma 5-HIAA, or a urine 24-hour 5-HIAA or plasma secretory hormone levels (VIP, gastrin) above the upper limit of normal per reference lab. Patients may be grouped into this cohort based on a previous plasma 5-HIAA level though the final cohort determination will be made based upon the 5-HIAA level drawn during screening.~Non-Carcinoid Syndrome:~Participants who have histopathologically confirmed neuroendocrine tumor and have 4 or more bowel movements per day on standard anti-diarrheal regimen (which may or may not include somatostatin analogs), but do not have elevated results for one of the following: plasma 5-HIAA, or 24-hour urine 5-HIAA or other plasma secretory hormone levels (VIP, gastrin) above the upper limit of normal per reference lab. Patients may be grouped into this cohort based on a previous plasma 5-HIAA level though the final cohort determination will be made based upon the 5-HIAA level drawn during screening~* ECOG performance status ≤ 2 (Karnofsky ≥60%)~* Ability to tolerate thin liquids by mouth at the time of enrollment.~* Ability to understand and the willingness to sign a written informed consent document.~* Subject who are willing to take enterade® as instructed will be eligible.~Exclusion Criteria:~* Known allergy to Stevia.~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active~* Clostridium difficile infection or history of Clostridium difficile infection.~* Participants with a history of inflammatory bowel disease, irritable bowel syndrome, bariatric surgery and/or Celiac disease.~* Participants with psychiatric illness/social situations that would limit compliance with study requirements.~* Patients who have had enterade® within the past 3 months.~* Pregnant or breastfeeding women. The safety of enterade® has not been validated in this patient population.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enterade (Type: EXPERIMENTAL): Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
- Experimental (Type: EXPERIMENTAL): Non-Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).